Avoiding Aspirin in the Elderly: More Than Increased Bleeding Risk - Frankly Speaking EP 260Guest: Jillian Joseph, MSPAS, PA-C
Music Credit: Richard Onorato
Frankly Speaking, Live!
In this episode, recorded live at Pri-Med East, we will review the current USPSTF recommendations regarding aspirin use to reduce the risk of CVD and colorectal cancer. Additionally, we will discuss as well as the findings of the ASPREE (ASPirin in reducing events in the elderly) randomized clinical trial.
Episode references and resource links:
POEMs: In Older Adults, Aspirin Increases the Risk of Metastatic of Stage 4 Cancers and Cancer Mortality. Barry, Henry C. Am Fam Physician. 2021 Sep; 104(2):online
Effect of Aspirin on Cancer Incidence and Mortality in Older Adults. McNeil, John. JNCI: Journal of the National Cancer Institute Volume: 113 Issue 3 (2021) ISSN: 0027-8874 Online ISSN: 1460-2105
Already listened on another platform?
- Identify when aspirin is beneficial to reduce risk of CVD and cancer
- Describe when aspirin might be harmful for elderly patients
Frank J. Domino, MD
Professor, Family Medicine and Community Health,
University of Massachusetts Medical School, Worcester, MA
Jillian Joseph, MPAS, PA-C
Assistant Professor, Department of PA Studies, Massachusetts College of Pharmacy, Boston, MA
Clinical Instructor, Department of Family Medicine & Community Health, University of Massachusetts Medical School, Worcester, MA
The following financial relationships have been disclosed by faculty.
Frank J. Domino, MD
Has disclosed no relevant financial relationships.
Jillian Joseph, MPAS, PA-C
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
Supporters and Partners
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email email@example.com or call (877) 477-4633.